Retrospective Analysis of Corticosteroid Treatment in Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis over a Period of 10 Years in Vajira Hospital, Navamindradhiraj University, Bangkok

Table 1

Clinical characteristics of Stevens-Johnson syndrome and/or toxic epidermal necrolysis cases from 2003 to 2012 (𝑛=87).

	2008–2012; (𝑛=51), 𝑛 (%)	2003–2007; (𝑛=36), 𝑛 (%)	𝑃 value
Age (years)	49.3±19.2	42.6±21.0	0.104
Male	27 (52.9)	17 (47.2)	0.599
Underlying diseases
Cardiovascular disease	11 (21.5)	8 (22.2)	0.942
Diabetes mellitus	7 (13.7)	5 (13.8)	0.983
HIV infection	12 (23.5)	9 (25.0)	0.875
Malignancy*	7 (13.7)	0 (0)	0.033
Diagnosis
SJS	36 (70.6)	26 (72.2)	0.868
SJS-TEN overlap	7 (13.7)	1 (2.8)	0.082
TEN	8 (15.7)	9 (25.0)	0.281
Mucosal involvement
Ocular	40 (78.4)	32 (88.8)	0.203
Mouth	45 (88.2)	35 (97.2)	0.129
Genitalia*	27 (52.9)	11 (30.5)	0.038
Urethra*	2 (3.9)	7 (19.4)	0.019
Anus	3 (5.8)	1 (2.8)	0.496
SCORTEN
≤1	16 (31.4)	13 (36.1)	0.664
2	19 (37.3)	19 (52.8)	0.151
3	12 (23.5)	3 (8.3)	0.065
4	1 (1.9)	1 (2.8)	0.802
≥5	3 (5.8)	0 (0)	0.139
Causes of disease
Single drug-related	44 (86.3)	30 (83.3)	0.705
Multiple drug-related	7 (13.7)	6 (16.6)	0.705
Intravenous steroid use**	39 (76.5)	8 (22.2)	<0.001
Dexamethasone equivalent doses (mg/day)	13.2±6.1	14.5±6.3	0.914
Steroid treatment duration (day)	5.7±2.7	5.4±2.5	0.810
Steroid treatment duration of ≥7 days	13 (33.3)	4 (50.0)	0.096

^∗𝑃<0.05,^∗∗𝑃<0.01.
SJS: Stevens-Johnson syndrome.
TEN: toxic epidermal necrolysis.